Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) reported $608 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 11.6%. EPS of $0.96 for the same period compares to $0.85 a year ago.

The reported revenue represents a surprise of +1.19% over the Zacks Consensus Estimate of $600.83 million. With the consensus EPS estimate being $0.95, the EPS surprise was +1.05%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Royalty Receipts- Growth Products- Cystic fibrosis franchise

  : $194.78 million compared to the $199.21 million average estimate based on two analysts. The reported number represents a change of -5.5% year over year.

• Revenue- Royalty Receipts- Growth Products- Tysabri

  : $63.86 million versus the two-analyst average estimate of $63.75 million. The reported number represents a year-over-year change of -24.3%.

• Revenue- Royalty Receipts- Growth Products- Imbruvica

  : $49.13 million compared to the $46.25 million average estimate based on two analysts. The reported number represents a change of -21.7% year over year.

• Revenue- Royalty Receipts- Growth Products- Xtandi

  : $38.62 million versus $37.76 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.6% change.

• Revenue- Royalty Receipts- Growth Products- Promacta

  : $30.50 million compared to the $31.20 million average estimate based on two analysts. The reported number represents a change of -21.2% year over year.

• Revenue- Royalty Receipts- Growth Products- Trelegy

  : $48.49 million versus $46.44 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +32.5% change.

• Revenue- Royalty Receipts- Growth Products- Nurtec ODT

  : $3.93 million compared to the $3.97 million average estimate based on two analysts. The reported number represents a change of -6.1% year over year.

• Revenue- Royalty Receipts- Growth Products- Cabometyx/Cometriq

  : $16.74 million compared to the $16.79 million average estimate based on two analysts. The reported number represents a change of +9% year over year.

• Revenue- Royalty Receipts- Growth Products- Evrysdi

  : $24.93 million compared to the $25.25 million average estimate based on two analysts. The reported number represents a change of +91.2% year over year.

• Revenue- Royalty Receipts- Growth Products- Trodelvy

  : $10.39 million versus the two-analyst average estimate of $10.70 million. The reported number represents a year-over-year change of +13.3%.

• Revenue- Royalty Receipts- Growth Products- Tremfya

  : $29.90 million compared to the $31.15 million average estimate based on two analysts. The reported number represents a change of +33.9% year over year.

View all Key Company Metrics for Royalty Pharma here>>>

Shares of Royalty Pharma have returned +5.9% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.